


# ESR1 Mutation Surveillance is Coming.

## Are You Ready?

*ESR1* mutations are acquired in up to 40% of HR+/HER2- mBC patients with prolonged exposure to endocrine therapies such as aromatase inhibitors.<sup>1</sup> Emerging clinical data has shown that routine monitoring for *ESR1* mutations followed by early intervention of novel, effective therapies can help prolong progression-free survival and improve quality of life for these patients.<sup>2,3</sup>

With *ESR1* surveillance still emerging but rapidly growing in clinical interest, laboratories may not be equipped to support your testing needs today. Until your partner laboratory is locally validated with a solution to support you in perpetuity, the Asuragen Clinical Laboratory is available to support your *ESR1* testing needs immediately with



ultra-sensitive, fast, and targeted testing for the most common, pathogenic variants in *ESR1*, providing greater confidence in your results. In the meantime, Asuragen can help support your partner laboratory through validation to help provide continuous and seamless *ESR1* testing services today and well into the future.

## ESR1 Testing Process

1

### Order Test via Laboratory Partner

Establish Lab Services Agreement to facilitate fast, simple ordering.



2

### Collect/Process Blood Sample and Send to Asuragen Clinical Laboratory

Collect 2x10 mL K<sub>2</sub>EDTA whole blood and spin down to plasma. Ship on dry ice.



3

### ESR1 Testing at Asuragen Clinical Laboratory

Sample processing and ultra-sensitive *ESR1* mutation detection.



4

### Sample Results

Reported within 7 business days of sample receipt.



# Test Overview

<b>Technology</b>	RT-qPCR
<b>Coverage</b>	E380Q, V422del, S463P, L536H/P/R, Y537S/N/C/D, D538G
<b>Sample</b>	2×10 mL Whole Blood (K <sub>2</sub> EDTA), spun down to plasma within 4 hours Plasma shipped frozen on dry ice
<b>Assay Sensitivity</b>	0.03–0.11% VAF

## Key Benefits




### Focused Coverage

Screens for the most common *ESR1* ligand-binding domain mutations with known pathogenicity



### Ultra-Sensitive

Detect variants earlier at ultra-low levels



### Fast

Results within 7 business days from sample receipt

## CONTACT US

Asuragen Clinical Laboratory  
2150 Woodward St., Ste. 100  
Austin, TX 78744  
(877) 777 1874

[CLIAServices@bio-techne.com](mailto:CLIAServices@bio-techne.com)



**Learn More About Our  
ESR1 Testing Services**

1. BreastCancer.org. *Metastatic Breast Cancer*. Available at: <https://www.breastcancer.org/types/metastatic>. Last Accessed: 6 February 2026
2. Bidard FC, et al. *N Engl J Med* 2025;393:569-580
3. Bidard FC, et al. *The Lancet Oncology* 2022;23:11, 1367-1377

This test was developed and its performance characteristics determined by Asuragen Clinical Services. It has not been cleared or approved by the FDA. The laboratory is regulated under CLIA as qualified to perform high-complexity testing. This test is used for clinical purposes. It should not be regarded as investigational or for research.  
40301.0.0226

**biotechne** / Global Developer, Manufacturer, and Supplier of High-Quality Reagents, Analytical Instruments, and Precision Diagnostics.

INCLUDES

R&D Systems™

Novus Biologicals™

Tocris Bioscience™

ProteinSimple™

Asuragen®

ACD™

Lunaphore™